|
Kaposi Sarcoma and HHV8 in Sickle Cell and Other Ugandan Populations
|
Research Initiative
|
CDC
|
NCI
|
Epidemiological studies are being conducted to assess small-area variation of Kaposi''s sarcoma-associated herpesvirus (HHV8) and to learn about socio-demographical and environmental risk factors for HHV8 and Kaposi sarcoma in Uganda.
|
|
Kidney, Urologic, & Hematologic Diseases Interagency Coordinating Committee
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS
|
NIDDK, NCCIH, NCI, NHLBI, NIA, NICHD, NINDS
|
The Kidney, Urologic, and Hematologic Diseases Interagency Coordinating Committee (KUHICC) encourages cooperation, communication, and collaboration among all Federal agencies involved in kidney, urology, and hematology research and other activities. Section 429 of Public Law 99-158 created the KUHICC in 1987. The committee met for the first time in 1988, and has the following subcommittees: Kidney Interagency Coordinating Committee, Urology Subcommittee, and Hematology Subcommittee. Meetings focus on interagency collaboration to elicit ideas from meeting participants to enhance current research directions within the National Institutes of Health and to form partnerships among agencies.
|
|
KidneyX (Kidney Innovation Accelerator)
|
Research Initiative
|
CMS, FDA
|
NIDDK
|
KidneyX, also called the Kidney Innovation Accelerator, is a public-private partnership between the U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN). Established in April 2018, KidneyX aims to use prize competitions to accelerate the development of innovative solutions that can prevent, diagnose, and/or treat kidney diseases. KidneyX aims to promote collaboration between patients, health professionals, innovators, industry, and government with the ultimate goal of improving quality of life for people living with kidney diseases.
|
|
Leprosy Research Support in Armadillos (Dasypus Novemcinctus)
|
Other
|
HRSA
|
NIAID
|
The Leprosy Research Support and Maintenance of an Armadillo Colony – Post Genome Era interagency agreement provides standardized research reagents to investigators worldwide to assist in the development of skin test antigens used to detect leprosy. This agreement supports collaborative research to continuously improve biochemical, microbiological, and immunological models for leprosy research in an effort to provide the most up-to-date resource and expertise for mycobacterial researchers.
|
|
LGBT Healthy People 2030 Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, AHRQ, ATSDR, BARDA, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA
|
OD/DPSCSI/SGMRO, NCI, NEI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIMH, NINDS, OD/DPCPSI/ODP
|
Healthy People provides science-based national goals and objectives with 10-year targets designed to guide national health promotion and disease prevention efforts to improve the health of all Americans. As part of its mission, Healthy People has established benchmarks and monitored progress over three decades in order to (1) engage multiple sectors to strengthen policies and improve practices that are driven by the best available evidence and (2) to increase public awareness of the determinants of health, disease, and disability and the opportunities for progress.
|
|
Library of Integrated Network-based Cellular Signatures (LINCS)
|
Research Initiative
|
FDA
|
OD/DPCPSI/OSC, NHGRI, NHLBI
|
The Library of Integrated Network-based Cellular Signatures (LINCS) program is developing a library of data at the cellular level that describes how different types of cells respond to a variety of agents that disrupt normal cellular functions, called “perturbagens.” This library may help us better understand normal and diseased conditions in cells and how to alter them. The LINCS program engages with the Food and Drug Administration (FDA) regarding how LINCS data may be used to predict drug toxicity.
|
|
Linkage of Surveillance, Epidemiology, End Results data to Centers for Medicare and Medicaid data
|
Resource Development
|
CMS
|
NCI
|
The Surveillance, Epidemiology, End Results (SEER) registry data (e.g., cancer diagnosis date, site, histology) are individually linked to Centers for Medicare and Medicaid Services (CMS) data (e.g., enrollment, claims, assessments and surveys) using personally identifiable information. The data on the matching cancer cases are pulled together with CMS data on non-cancer controls (e.g., individuals not known to have a cancer diagnosis who reside in a SEER area) to create four research data resources: SEER-Medicare, SEER-Medicare Health Outcomes Survey (SEER-MHOS), SEER-Consumer Assessment of Healthcare Providers and Systems (SEER-CAHPS) and SEER-Medicaid.
|
|
Logical Observation Identifiers Names and Codes (LOINC)
|
Resource Development
|
AHRQ, CDC, CMS, HRSA, IHS, OS
|
NLM
|
This activity supports the maintenance, distribution, and continued development of LOINC®, a set of universal codes and names to identify laboratory and other clinical observations which facilitates the exchange and pooling of clinical results for clinical care, outcomes management, public health, and research. The Regenstrief Institute, Inc., an internationally renowned healthcare and informatics research organization, maintains the LOINC database and supporting documentation, and the RELMA mapping program.
|
|
Lower Limb Prosthetics Research Standards Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ACL, AHRQ, CMS, FDA
|
NICHD, NIDDK
|
This working group helps to determine research standards for lower limb prosthetics.
|
|
Lupus Federal Working Group
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, HRSA, OS
|
NIAMS, NCCIH, NEI, NHLBI, NIAID, NICHD, NIDCR, NIDDK, NIEHS, NIMHD, NINDS, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH
|
The Lupus Federal Working Group, established on behalf of the Department of Health and Human Services (HHS) Secretary by the National Institutes of Health (NIH), facilitates collaboration among NIH components, other Federal agencies, voluntary and professional organizations, and industry groups with an interest in lupus.
|